Ignite Creation Date:
2025-12-24 @ 11:57 PM
Ignite Modification Date:
2026-04-16 @ 7:50 AM
Study NCT ID:
NCT00394251
Status:
COMPLETED
Last Update Posted:
2019-11-25
First Post:
2006-10-30
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
Sponsor:
Celgene
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2006-08-01
Start Date Type:
ACTUAL
Primary Completion Date:
2007-03-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2008-02-01
Completion Date Type:
ACTUAL
First Submit Date:
2006-10-30
First Submit QC Date:
None
Study First Post Date:
2006-10-31
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2010-11-02
Results First Submit QC Date:
None
Results First Post Date:
2013-07-18
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-11-07
Last Update Post Date:
2019-11-25
Last Update Post Date Type:
ACTUAL